Bod Science Limited Stock

Equities

BOD

AU0000181331

Pharmaceuticals

Market Closed - Australian S.E. 11:59:52 2023-11-22 pm EST 5-day change 1st Jan Change
0.024 AUD -7.69% Intraday chart for Bod Science Limited -.--% -.--%
Sales 2022 5.09M 3.26M Sales 2023 3.32M 2.13M Capitalization 10.57M 6.78M
Net income 2022 -5M -3.21M Net income 2023 -7M -4.49M EV / Sales 2022 0.74 x
Net cash position 2022 3.67M 2.35M Net cash position 2023 1.07M 685K EV / Sales 2023 2.86 x
P/E ratio 2022
-1.37 x
P/E ratio 2023
-1.23 x
Employees -
Yield 2022 *
-
Yield 2023
-
Free-Float 66.39%
More Fundamentals * Assessed data
Dynamic Chart
1 day-7.69%
6 months-52.00%
More quotes
1 year
0.02
Extreme 0.024
0.13
3 years
0.02
Extreme 0.024
0.50
5 years
0.02
Extreme 0.024
0.74
10 years
0.02
Extreme 0.024
0.74
More quotes
Managers TitleAgeSince
Founder - 14-08-12
Director of Finance/CFO - 21-08-01
Corporate Secretary - 23-01-22
Members of the board TitleAgeSince
Chairman - 22-04-03
Founder - 14-08-12
Director/Board Member - 18-08-31
More insiders
Bod Science Limited is an Australia-based cannabis focused drug development and product innovation company. The Company is focused on progressing research and development with a defined clinical trial pathway to commercialize and deliver products for patients and consumers. The principal activities of the Company are the development and distribution of therapeutic medicinal cannabis products based on good manufacturing practice (GMP) certified cannabis extracts for medical markets in Australia and the United Kingdom, as well as the development of cannabidiol (CBD) and hemp products for consumer markets in Australia, the United Kingdom, Europe, and United States. The Company operates through three segments: medical, over the counter cannabidiol/Hemp (OTC CBD/Hemp) and OTC Herbals. The Company offers products for health and wellness, joint/muscle pain and general wellbeing, and stress/anxiety and sleep. The Company also owns the Aqua Phase delivery technology.
More about the company